Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Latest news articles

Added 4 days ago Drug news

Phase III CAFÉ study of Dupixent (dupilumab) in adults with moderate-to-severe atopic dermatitis where cyclosporine A isinadvisable.- Sanofi + Regeneron.

Sanofi and Regeneron Pharmaceuticals, Inc. announced positive results from the Phase III CAFÉ study of Dupixent (dupilumab) in adults with...

Added 4 days ago Drug news

OPTIMA study shows urticaria patients respond well to re- treatment with Xolair (omalizumab)-Novartis.

Novartis,announced new data showing almost 90% of chronic spontaneous urticaria (CSU) patients who responded well to initial Xolair (omalizumab) treatment...

Added 5 days ago Drug news

CHMP recommends approval of Tremfya (guselkumab) in the treatment of adults with moderate to severe plaque psoriasis.- Janssen-Cilag.

Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing...

Search all news articles for Dermatology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

+ 3 more

Visit Chronic Spontaneous Urticaria (CSU)

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

Visit IL-17A in Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

Visit Psoriasis

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 1 more

Visit Prostate Cancer

 

Guidelines

Psoriasis overview NICE Pathways

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.

Added 7 months ago

Canadian Guidelines for the Management of Plaque Psoriasis 2009

Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases. 

Added 7 months ago

Adalimumab for treating moderate to severe hidradenitis suppurativa

Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

Added 7 months ago

Search all guidelines for Dermatology
 

Journal articles

Nivolumab plus ipilimumab in advanced melanoma.

In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab...

Added 6 days ago

High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.

Systemic high-dose interleukin-2 (IL-2) achieved long-term survival in a subset of patients with advanced melanoma.

Added 6 days ago

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Melanoma is the deadliest form of skin cancer and its incidence has been increasing.

Added 6 days ago

Search all journal articles for Dermatology
 

Clinical trials

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 7 months ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 7 months ago

Search all clinical trials for Dermatology
 

Blog Posts

Hugh Harvey

Metrics Madness

Posted 1 year ago

You shouldn't judge a book by its cover. That much is true, but it's also common sense not to judge a book by measuring the whiteness of its pages, or the amount of hamsters you can place on it. So why do we measure the fabulous NHS with nonsense metrics?

CME

Ask an expert: Psoriasis

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Management of hidradenitis suppurativa

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Dermatology